Abstract
Historically, the immune environment was not considered an important target for breast cancer treatment. However, the association of lymphocytic infiltrates in triple negative and HER-2 over-amplified breast cancer subtypes with better outcomes, has provoked interest in evaluating the role of the immune system in the luminal B subtype that accounts for 39% of breast cancers and has a poor patient prognosis. It is unknown which immunosuppressive cell types or molecules (e.g., checkpoint molecules) are relevant, or where measurement is most informative. We hypothesize that a profound immunosuppressive tumor and/or lymph node milieu is prognostic and impacts on responses to therapies.
Original language | English |
---|---|
Article number | e1282590 |
Number of pages | 10 |
Journal | OncoImmunology |
Volume | 6 |
Issue number | 3 |
DOIs | |
Publication status | Published - 19 Jan 2017 |
Externally published | Yes |